Atlas Trials

Ann Arbor Stage III Non-Hodgkin Lymphoma

6 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Ann Arbor Stage III Non-Hodgkin Lymphoma

RecordFirmDate
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524)OHSU Knight Cancer Institute2020-04-01
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678)National Cancer Institute (NCI)2017-11-28
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665)National Cancer Institute (NCI)2017-11-13
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)National Cancer Institute (NCI)2017-07-31
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (NCT00972478)National Cancer Institute (NCI)2010-11-15
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (NCT00740805)National Cancer Institute (NCI)2008-08-18

Track Ann Arbor Stage III Non-Hodgkin Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.